Φορτώνει......
Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward?
As evidenced by the recent approvals of Removab (EU, Trion Pharma) in 2009 and of Blincyto (US, Amgen) in 2014, the high potential of bispecific antibodies in the field of immuno-oncology is eliciting a renewed interest from pharmaceutical companies. Supported by rapid advances in antibody engineeri...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Antibodies (Basel) |
|---|---|
| Κύριοι συγγραφείς: | , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
MDPI
2015
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6698871/ https://ncbi.nlm.nih.gov/pubmed/31557983 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/antib5010001 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|